Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

To be considered for this study, you must have advanced non-small cell lung cancer that has been confirmed by a doctor, and your cancer must have progressed despite previous treatment. This previous treatment should have included both chemotherapy and a type of immunotherapy. You must be well enough to take part, meaning you can carry out most of your daily activities, and doctors will check your general health, including your organ function, to make sure you are suitable.

You also need to have areas of cancer that can be measured by scans. If you have a specific type of lung cancer called squamous cell carcinoma, you don't need to have had specific genetic tests. However, if you have non-squamous lung cancer, your doctors will need to confirm that your cancer doesn't have certain genetic changes (called EGFR, ALK, or ROS-1 mutations) that would mean other treatments are more appropriate for you.

There are also reasons why you might not be able to join the study. For instance, if you've had a serious side effect from a previous immunotherapy that led to you stopping it permanently, or if you've already had certain other types of immunotherapy or chemotherapy drug (like docetaxel) for your advanced cancer. Also, if your cancer has shown signs of growing very quickly after recent treatments, you might not be eligible. This study is for adults aged 18 years and older, regardless of gender.

If you are eligible and choose to take part in this study, you will be assigned to one of three different treatment groups. You will receive a combination of medicines through infusions (into a vein) over a period of time. You will have regular hospital visits for your treatments, blood tests, and scans to monitor your health and how the cancer is responding to the treatment. The frequency of these visits and assessments will be explained in detail by the study team. You'll also be asked to provide a sample of your tumour tissue, either from a past biopsy or by having a new biopsy if needed. The total duration of your participation will depend on how you respond to the treatment and your health, but you will undergo regular follow-up for a period after treatment ends.